Department of Infectious Diseases, The Affiliated Hospital of Southwest Medical University, Luzhou, China.
Southwest Medical University, Luzhou, Sichuan, China.
J Clin Microbiol. 2021 Jul 19;59(8):e0300320. doi: 10.1128/JCM.03003-20.
Rapid and accurate identification of staphylococcal pneumonia is crucial for effective antimicrobial stewardship. We performed a meta-analysis to evaluate the diagnostic value of nucleic acid amplification tests (NAAT) from lower respiratory tract (LRT) samples from suspected pneumonia patients to avoid superfluous empirical methicillin-resistant Staphylococcus aureus (MRSA) treatment. PubMed, Scopus, Embase, Web of Science, and the Cochrane Library Database were searched from inception to 2 September 2020. Data analysis was carried out using a bivariate random-effects model to estimate pooled sensitivity, specificity, positive likelihood ratio (PLR), and negative likelihood ratio (NLR). Of 1,808 citations, 24 publications comprising 32 data sets met our inclusion criteria. Twenty-two studies (= 4,630) assessed the accuracy of the NAAT for methicillin-sensitive S. aureus (MSSA) detection, while 10 studies (= 2,996) demonstrated the accuracy of the NAAT for MRSA detection. The pooled NAAT sensitivity and specificity (with 95% confidence interval [CI]) for all MSSA detection were higher (sensitivity of 0.91 [95% CI, 0.89 to 0.94], specificity of 0.94 [95% CI, 0.94 to 0.95]) than those of MRSA (sensitivity of 0.75 [95% CI, 0.69 to 0.80], specificity of 0.88 [95% CI, 0.86 to 0.89]) in lower respiratory tract (LRT) samples. NAAT pooled sensitivities differed marginally among different LRT samples, including sputum, endotracheal aspirate (ETA), and bronchoalveolar lavage (BAL) fluid. Noticeably, NAAT pooled specificity against microbiological culture was consistently ≥88% across various types of LRT samples. A meta-regression and subgroup analysis of study design, sample condition, and patient selection method could not explain the heterogeneity ( > 0.05) in the diagnostic efficiency. This meta-analysis has demonstrated that the NAAT can be applied as the preferred initial test for timely diagnosis of staphylococcal pneumonia in LRT samples for successful antimicrobial therapy.
快速准确地识别金黄色葡萄球菌肺炎对于有效的抗菌药物管理至关重要。我们进行了一项荟萃分析,以评估从疑似肺炎患者的下呼吸道 (LRT) 样本中进行核酸扩增检测 (NAAT) 的诊断价值,以避免不必要的经验性耐甲氧西林金黄色葡萄球菌 (MRSA) 治疗。从 2020 年 9 月 2 日开始,我们在 PubMed、Scopus、Embase、Web of Science 和 Cochrane 图书馆数据库中进行了搜索。使用双变量随机效应模型分析数据,以估计合并的敏感性、特异性、阳性似然比 (PLR) 和阴性似然比 (NLR)。在 1808 条引文,24 篇出版物包含 32 个数据集符合我们的纳入标准。22 项研究(= 4630)评估了 NAAT 对甲氧西林敏感金黄色葡萄球菌(MSSA)检测的准确性,而 10 项研究(= 2996)则证明了 NAAT 对 MRSA 检测的准确性。所有 MSSA 检测的合并 NAAT 敏感性和特异性(95%置信区间 [CI])较高(敏感性为 0.91 [95%CI,0.89 至 0.94],特异性为 0.94 [95%CI,0.94 至 0.95]),而 MRSA(敏感性为 0.75 [95%CI,0.69 至 0.80],特异性为 0.88 [95%CI,0.86 至 0.89])在 LRT 样本中。NAAT 在不同的 LRT 样本中的敏感性差异不大,包括痰、气管抽吸物(ETA)和支气管肺泡灌洗液。值得注意的是,NAAT 对微生物培养的特异性在各种类型的 LRT 样本中均一致≥88%。元回归和亚组分析研究设计、样本条件和患者选择方法不能解释诊断效率的异质性(> 0.05)。这项荟萃分析表明,NAAT 可作为及时诊断 LRT 样本中金黄色葡萄球菌肺炎的首选初始检测方法,以进行成功的抗菌治疗。